Alder BioPharmaceuticals to Host Conference Call to Discuss Third Quarter 2016 Financial and Operating Results
October 20 2016 - 8:00AM
Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage
biopharmaceutical company developing monoclonal antibody
therapeutics, today announced that it will report its third
quarter 2016 financial and operating results after the close of
U.S. financial markets on Thursday, October 27,
2016. Alder management will host a conference call and live
audio webcast to discuss the results and provide a general business
update at 5:00 p.m. ET the same day.
The live call may be accessed by dialing (877) 430-4657 for
domestic callers or (484) 756-4339 for international callers, and
providing conference ID number 94584081. The webcast may be
accessed from the Events & Presentations page on the Investors
section of Alder’s website at www.alderbio.com and will
be available for replay following the call for 30 days.
About Alder
BioPharmaceuticals
Alder BioPharmaceuticals, Inc., is a clinical-stage
biopharmaceutical company that discovers, develops and seeks to
commercialize genetically engineered therapeutic antibodies with
the potential to meaningfully transform current treatment
paradigms. Alder's lead pivotal-stage product candidate, ALD403, is
being evaluated for migraine prevention. ALD403 is a monoclonal
antibody that inhibits calcitonin gene-related peptide (CGRP), a
protein that is active in mediating the initiation of migraine.
Alder is additionally evaluating ALD1910, a preclinical product
candidate also in development as a migraine prevention therapy.
ALD1910 is a monoclonal antibody that inhibits pituitary adenylate
cyclase-activating polypeptide-38 (PACAP-38), another protein that
is active in mediating the initiation of migraine. Clazakizumab,
Alder's third program, is a monoclonal antibody candidate that
inhibits interleukin-6 and is licensed to Vitaeris, Inc. For more
information, please visit http://www.alderbio.com.
Media Contacts:
David Schull or Todd Davenport, Ph.D.
Russo Partners, LLC
(212) 845-4271
(212) 845-4235
david.schull@russopartnersllc.com
todd.davenport@russopartnersllc.com
Investor Relations Contact:
David Walsey
Alder BioPharmaceuticals Inc.
(425) 408-8032
ir@alderbio.com
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alder BioPharmaceuticals (NASDAQ:ALDR)
Historical Stock Chart
From Sep 2023 to Sep 2024